Novavax, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two…
Codagenix, a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, announced a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the emergent coronavirus. There are no licensed vaccines or therapeutics for this novel coronavirus, now referred to as COVID-19. A live-attenuated vaccine has multiple advantages, including mounting…